Answers are grounded in this paper and cite their sources.
A factor IX concentrate, prepared by modifications of the method of Tullis and with the supernatant of fraction 1‐0 as a base material, has become available in Sweden. The factor IX activity of the concentrate is about 20 times that of an equivalent volume of normal plasma. The factor IX concentrate, altogether 226 bottles, has been given to 18 patients with haemophilia B in connection with major and minor surgical procedures (7 patients) and bleeding episodes such as joint bleeding, renal bleeding and large haematomas. After injection abnormal bleeding was arrested and the surgical procedures could be performed without any haemorrhagic complications. The factor IX activity in vivo ranged from 16 to 69% (average 38%) of the in vitro activity of the concentrates administered. The half‐life of the injected factor IX was about 20 hours. A dose of 10–16 units per kg b.wt. is recommended for raising the factor IX level to 16–20% and a dose of 30–40 units per kg b.wt. for raising it to at least 40%. Four patients developed hepatitis, but otherwise no side‐reactions were seen.
No takes yet. Share an insight, caveat, or question.
Nilsson et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: